Scientific Validation of Herbal Medicine

  • Vivek V. BhosaleEmail author
  • Dibyendu Banerjee


The value of the herbal medicine market size was USD 71.19 billion globally in 2016 and is expected to grow even more in the near future. The main obstacle to the growth of herbal medicine is its quality control. The scientific validation by standardization, evaluation of purity, and demonstration of its efficacy in animal models and in humans will increase the trust of users and increase its acceptability. There are various guidelines available for standardization of herbal medicines. Globally each country has its own rules and regulations. In the USA, guidelines for botanical drugs have been revised in 2016. The phytopharma guidelines also came in existence in India in 2015. The scientific validation of herbal drugs requires information regarding pharmacognostic description like taxonomic classification and quality specifications in which heavy metals, ash, and impurity data are important. The herbal medicines which are already used in human do not require any animal studies but if there are any changes in method of extraction and formulation then animal safety data is essential. The toxicity studies in two species are minimally required. The clinical trials are necessary to demonstrate its efficacy for newer drugs. The phase I clinical studies are conducted to assess the maximum tolerated dose of medicine and its safety. The proof of concept and confirmatory clinical trials should be conducted as randomized placebo control trials and as per good clinical practice norms. The regulatory requirements of herbal drugs for clinical trials and marketing permission may be abbreviated, modified or relaxed based on adequate evidence from market or research published in peer-reviewed journals. The current book chapter will discuss the requirements of herbal drugs and practical issue in scientific validation of herbal medicines.


Herbal medicine Herbal drugs Standardization Ayurveda Traditional medicine Regulatory guidelines 


  1. Anonymous. Quality assurance of pharmaceuticals - a compendium of guidelines and related materials, Vol. 1. 1997. Accessed 29 Apr 2019.
  2. Anonymous. Directive 2004/24/EC of the European Parliament and of The Council of 31 March 2004. Official Journal of the European Union. 2004. Accessed 29 Apr 2019.Google Scholar
  3. Bhatt A. Phytopharmaceuticals: a new drug class regulated in India. Perspect Clin Res. 2016;7(2):59–61.CrossRefGoogle Scholar
  4. Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH – Govt. of India. General guidelines for safety/toxicity evaluation of ayurvedic formulations. 2018. Accessed 29 Apr 2019.
  5. Department of AYUSH, Govt. of India. Good Clinical Practice Guidelines for Clinical Trials of ASU medicine. 2013. Accessed 29 Apr 2019
  6. Drugs and Cosmetics (Eighth Amendment) Rules, 2015, Ministry of Health and Family Welfare, Govt. of India. Gazette Notification G.S.R. 918(E). 2015. Accessed 29 Apr 2019.
  7. Firenzuoli F, Gori L. Herbal medicine today: clinical and research issues. Evid Based Complement Alternat Med. 2007;4(Suppl 1):37–40.CrossRefGoogle Scholar
  8. Food and Drug Administration, US. Botanical Drug Development Guidance for Industry. 2016. Accessed 29 Apr 2019
  9. Lele RD. Four new approaches for validation of Ayurvedic herbal drugs. Int J Ayurveda Res. 2010;1(3):136–7.CrossRefGoogle Scholar
  10. Leung PC. Complementary medicine. In: Machin D, Day S, Green S, editors. Textbook of clinical trials. 1st ed. Chichester: John Wiley & Sons; 2004. p. 63–84.CrossRefGoogle Scholar
  11. Narayana DA, Katiyar C. Draft amendment to drugs and cosmetics rules to license science based botanicals phytopharmaceuticals as drugs in India. J Ayurveda Integr Med. 2013;4:245–6.CrossRefGoogle Scholar
  12. NewDrugs_CTRules_2019. New Drugs and Clinical Trials Rules 2019 G.S.R. 227(E), Ministry of health and family welfare, New Delhi, the 19th March, 2019. 2019. Accessed 30 Apr 2019.
  13. Parveen A, Parveen B, Parveen R, Ahmad S. Challenges and guidelines for clinical trial of herbal drugs. J Pharm Bioallied Sci. 2015;7(4):329–33.CrossRefGoogle Scholar
  14. Sharma S. Current status of herbal product: regulatory overview. J Pharm Bioallied Sci. 2015;7(4):293–6.CrossRefGoogle Scholar
  15. Walker LG, Anderson J. Testing complementary and alternative therapies within a research protocol. Eur J Cancer. 1999;35:1614–8.CrossRefGoogle Scholar
  16. WHO. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. 1993.
  17. WHO, guidelines for assessing quality of herbal medicines with reference to contaminants and residues. 2007a.
  18. WHO. Guidelines on Good Manufacturing Practices (GMP) for herbal medicines. 2007b.

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.CSIR- Central Drug Research Institute, CDRI communication number: 9854LucknowIndia
  2. 2.CSIR- Central Drug Research InstituteLucknowIndia

Personalised recommendations